---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-000029"
form_type: "8-K"
ticker: "SRRK"
cik: "0001727196"
company_name: "Scholar Rock Holding Corp"
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:01:46.969230+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Scholar Rock updates 2023 pipeline priorities; Phase 3 SMA trial enrollment completion expected in 2023

## Summary
- Phase 3 SAPPHIRE trial enrollment to complete in 2023; top-line data expected in 2024, potential launch in 2025.
- Cash, cash equivalents and marketable securities ~$315M as of Dec 31, 2022; runway into 2025.
- 36-month TOPAZ extension data expected H1 2023; 90% of patients remain enrolled in long-term extension.
- Preclinical fibrosis and iron-restricted anemia programs advancing toward IND-enabling studies.
- Jay Backstrom appointed President & CEO (Oct 2022); Jing Marantz appointed CMO (Nov 2022).

## SEC filing metadata
- accession: 0001157523-23-000029
- form_type: 8-K
- ticker: SRRK
- cik: 0001727196
- company_name: Scholar Rock Holding Corp
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1727196/000115752323000029/0001157523-23-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1727196/000115752323000029/a53178569.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-000029
- JSON: https://secwatch.observer/filing/0001157523-23-000029.json
- Plain text: https://secwatch.observer/filing/0001157523-23-000029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.